{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:49:54Z","timestamp":1793332194174,"version":"4.5.0"},"reference-count":237,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T00:00:00Z","timestamp":1552348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1038\/s41582-019-0155-7","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T14:03:44Z","timestamp":1552485824000},"page":"204-223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":289,"title":["Emerging therapies in Parkinson disease \u2014 repurposed drugs and new approaches"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4296-5236","authenticated-orcid":false,"given":"Ahmad","family":"Elkouzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinata","family":"Vedam-Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3191-2355","authenticated-orcid":false,"given":"Robert S.","family":"Eisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Okun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,12]]},"reference":[{"key":"155_CR1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia, L. V. & Lang, A. E. Parkinson\u2019s disease. Lancet 386, 896\u2013912 (2015).","journal-title":"Lancet"},{"key":"155_CR2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/mds.27360","volume":"33","author":"AE Lang","year":"2018","unstructured":"Lang, A. E. & Espay, A. J. Disease modification in Parkinson\u2019s disease: current approaches, challenges, and future considerations. Mov. Disord. 33, 660\u2013677 (2018).","journal-title":"Mov. Disord."},{"key":"155_CR3","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/mds.23116","volume":"25","author":"SM Rooden Van","year":"2010","unstructured":"Van Rooden, S. M. et al. The identification of Parkinson\u2019s disease subtypes using cluster analysis: a systematic review. Mov. Disord. 25, 969\u2013978 (2010).","journal-title":"Mov. Disord."},{"key":"155_CR4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/jnnp-2012-303455","volume":"84","author":"C Marras","year":"2013","unstructured":"Marras, C. & Lang, A. Parkinson\u2019s disease subtypes: lost in translation? J. Neurol. Neurosurg. Psychiatry 84, 409\u2013415 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"155_CR5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrn.2017.62","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira, A. H. V., Chaudhuri, K. R. & Jenner, P. Non-motor features of Parkinson disease. Nat. Rev. Neurosci. 18, 435\u2013450 (2017).","journal-title":"Nat. Rev. Neurosci."},{"key":"155_CR6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","volume":"5","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri, K. R., Healy, D. G. & Schapira, A. H. V. Non-motor symptoms of Parkinson\u2019s disease: diagnosis and management. Lancet Neurol. 5, 235\u2013245 (2006).","journal-title":"Lancet Neurol."},{"key":"155_CR7","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.parkreldis.2015.09.004","volume":"22","author":"RF Pfeiffer","year":"2016","unstructured":"Pfeiffer, R. F. Non-motor symptoms in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 22, S119\u2013S122 (2016).","journal-title":"Parkinsonism Relat. Disord."},{"key":"155_CR8","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos, M. H. et al. Mutation in the \u03b1-synuclein gene identified in families with Parkinson\u2019s disease. Science 276, 2045\u20132047 (1997).","journal-title":"Science"},{"key":"155_CR9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. et al. \u03b1-Synuclein in Lewy bodies. Nature 388, 839\u2013840 (1997).","journal-title":"Nature"},{"key":"155_CR10","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.neuron.2013.09.004","volume":"79","author":"JT Bendor","year":"2013","unstructured":"Bendor, J. T., Logan, T. P. & Edwards, R. H. The function of \u03b1-synuclein. Neuron 79, 1044\u20131066 (2013).","journal-title":"Neuron"},{"key":"155_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nm.4269","volume":"23","author":"YC Wong","year":"2017","unstructured":"Wong, Y. C. & Krainc, D. \u03b1-Synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat. Med. 23, 1\u201313 (2017).","journal-title":"Nat. Med."},{"key":"155_CR12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","volume":"14","author":"B Dehay","year":"2015","unstructured":"Dehay, B. et al. Targeting \u03b1-synuclein for treatment of Parkinson\u2019s disease: mechanistic and therapeutic considerations. Lancet Neurol. 14, 855\u2013866 (2015).","journal-title":"Lancet Neurol."},{"key":"155_CR13","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/3311","volume":"4","author":"KA Conway","year":"1998","unstructured":"Conway, K. A., Harper, J. D. & Lansbury, P. T. Accelerated in vitro fibril formation by a mutant \u03b1-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318\u20131320 (1998).","journal-title":"Nat. Med."},{"key":"155_CR14","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1126\/science.1101738","volume":"305","author":"AM Cuervo","year":"2004","unstructured":"Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T. & Sulzer, D. Impaired degradation of mutant \u03b1-synuclein by chaperone-mediated autophagy. Science 305, 1292\u20131295 (2004).","journal-title":"Science"},{"key":"155_CR15","first-page":"777","volume":"118","author":"M Martinez-Vicente","year":"2008","unstructured":"Martinez-Vicente, M. et al. Dopamine-modified \u03b1-synuclein blocks chaperone-mediated autophagy. J. Clin. Invest. 118, 777\u2013788 (2008).","journal-title":"J. Clin. Invest."},{"key":"155_CR16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.neulet.2010.09.061","volume":"486","author":"SJ Chinta","year":"2010","unstructured":"Chinta, S. J., Mallajosyula, J. K., Rane, A. & Andersen, J. K. Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci. Lett. 486, 235\u2013239 (2010).","journal-title":"Neurosci. Lett."},{"key":"155_CR17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1523\/JNEUROSCI.2507-13.2014","volume":"34","author":"C Guardia-Laguarta","year":"2014","unstructured":"Guardia-Laguarta, C. et al. \u03b1-Synuclein is localized to mitochondria-associated ER membranes. J. Neurosci. 34, 249\u2013259 (2014).","journal-title":"J. Neurosci."},{"key":"155_CR18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00401-017-1704-z","volume":"134","author":"S Paillusson","year":"2017","unstructured":"Paillusson, S. et al. \u03b1-Synuclein binds to the ER\u2013mitochondria tethering protein VAPB to disrupt Ca2+ homeostasis and mitochondrial ATP production. Acta Neuropathol. 134, 129\u2013149 (2017).","journal-title":"Acta Neuropathol."},{"key":"155_CR19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/mds.26935","volume":"32","author":"CW Olanow","year":"2017","unstructured":"Olanow, C. W. & Kordower, J. H. Targeting \u03b1-synuclein as a therapy for Parkinson\u2019s disease: the battle begins. Mov. Disord. 32, 203\u2013207 (2017).","journal-title":"Mov. Disord."},{"key":"155_CR20","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1126\/science.aaf3934","volume":"357","author":"S Mittal","year":"2017","unstructured":"Mittal, S. et al. \u03b22-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson\u2019s disease. Science 357, 891\u2013898 (2017).","journal-title":"Science"},{"key":"155_CR21","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ana.25341","volume":"84","author":"S Searles Nielsen","year":"2018","unstructured":"Searles Nielsen, S., Gross, A., Camacho-Soto, A., Willis, A. W. & Racette, B. A. \u03b22-adrenoreceptor medications and risk of Parkinson disease. Ann. Neurol. 84, 683\u2013693 (2018).","journal-title":"Ann. Neurol."},{"key":"155_CR22","doi-asserted-by":"crossref","first-page":"25009","DOI":"10.1074\/jbc.M300227200","volume":"278","author":"JL Webb","year":"2003","unstructured":"Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N. & Rubinsztein, D. C. \u03b1-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278, 25009\u201325013 (2003).","journal-title":"J. Biol. Chem."},{"key":"155_CR23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature09299","volume":"467","author":"BH Lee","year":"2010","unstructured":"Lee, B. H. et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467, 179\u2013184 (2010).","journal-title":"Nature"},{"key":"155_CR24","doi-asserted-by":"crossref","first-page":"12535","DOI":"10.1523\/JNEUROSCI.1920-10.2010","volume":"30","author":"B Dehay","year":"2010","unstructured":"Dehay, B. et al. Pathogenic lysosomal depletion in Parkinson\u2019s disease. J. Neurosci. 30, 12535\u201312544 (2010).","journal-title":"J. Neurosci."},{"key":"155_CR25","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.ymthe.2018.02.022","volume":"26","author":"A Torra","year":"2018","unstructured":"Torra, A. et al. Overexpression of TFEB drives a pleiotropic neurotrophic effect and prevents Parkinson\u2019s disease-related neurodegeneration. Mol. Ther. 26, 1552\u20131567 (2018).","journal-title":"Mol. Ther."},{"key":"155_CR26","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.4161\/auto.26451","volume":"9","author":"M Xilouri","year":"2013","unstructured":"Xilouri, M., Brekk, O. R., Kirik, D. & Stefanis, L. LAMP2A as a therapeutic target in Parkinson disease. Autophagy 9, 2166\u20132168 (2013).","journal-title":"Autophagy"},{"key":"155_CR27","doi-asserted-by":"crossref","first-page":"13578","DOI":"10.1523\/JNEUROSCI.4390-09.2009","volume":"29","author":"B Spencer","year":"2009","unstructured":"Spencer, B. et al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in -synuclein models of Parkinson\u2019s and Lewy body diseases. J. Neurosci. 29, 13578\u201313588 (2009).","journal-title":"J. Neurosci."},{"key":"155_CR28","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1523\/JNEUROSCI.3944-09.2010","volume":"30","author":"C Malagelada","year":"2010","unstructured":"Malagelada, C., Jin, Z. H., Jackson-Lewis, V., Przedborski, S. & Greene, L. A. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson\u2019s disease. J. Neurosci. 30, 1166\u20131175 (2010).","journal-title":"J. Neurosci."},{"key":"155_CR29","doi-asserted-by":"crossref","DOI":"10.1038\/srep04874","volume":"4","author":"SS Karuppagounder","year":"2014","unstructured":"Karuppagounder, S. S. et al. The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson\u2019s disease. Sci. Rep. 4, 4874 (2014).","journal-title":"Sci. Rep."},{"key":"155_CR30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JPD-160867","volume":"6","author":"F Pagan","year":"2016","unstructured":"Pagan, F. et al. Nilotinib effects in Parkinson\u2019s disease and dementia with lewy bodies. J. Parkinsons Dis. 6, 503\u2013517 (2016).","journal-title":"J. Parkinsons Dis."},{"issue":"Suppl. 2","key":"155_CR31","first-page":"238","volume":"33","author":"T Simuni","year":"2018","unstructured":"Simuni, T. et al. A phase 2a study of nilotinib in patients with advanced and early Parkinson\u2019s disease. study design [abstract]. Mov. Disord. 33 (Suppl. 2), 238 (2018).","journal-title":"Mov. Disord."},{"key":"155_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2014.04.003","volume":"68","author":"MH Savolainen","year":"2014","unstructured":"Savolainen, M. H. et al. The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on \u03b1-synuclein clearance and autophagy in A30P transgenic mouse. Neurobiol. Dis. 68, 1\u201315 (2014).","journal-title":"Neurobiol. Dis."},{"key":"155_CR33","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1476-5381.2012.01846.x","volume":"166","author":"TT My\u00f6h\u00e4nen","year":"2012","unstructured":"My\u00f6h\u00e4nen, T. T. et al. A prolyl oligopeptidase inhibitor, KYP-2047, reduces \u03b1-synuclein protein levels and aggregates in cellular and animal models of Parkinson\u2019s disease. Br. J. Pharmacol. 166, 1097\u20131113 (2012).","journal-title":"Br. J. Pharmacol."},{"key":"155_CR34","doi-asserted-by":"crossref","first-page":"E1009","DOI":"10.1073\/pnas.1610586114","volume":"114","author":"M Perni","year":"2017","unstructured":"Perni, M. et al. A natural product inhibits the initiation of \u03b1-synuclein aggregation and suppresses its toxicity. Proc. Natl Acad. Sci. USA 114, E1009\u2013E1017 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"155_CR35","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s13311-017-0544-9","volume":"14","author":"F Richter","year":"2017","unstructured":"Richter, F. et al. A molecular tweezer ameliorates motor deficits in mice overexpressing \u03b1-synuclein. Neurotherapeutics 14, 1107\u20131119 (2017).","journal-title":"Neurotherapeutics"},{"key":"155_CR36","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/ana.24066","volume":"75","author":"A Recasens","year":"2014","unstructured":"Recasens, A. et al. Lewy body extracts from Parkinson disease brains trigger \u03b1-synuclein pathology and neurodegeneration in mice and monkeys. Ann. Neurol. 75, 351\u2013362 (2014).","journal-title":"Ann. Neurol."},{"key":"155_CR37","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nm1747","volume":"14","author":"JH Kordower","year":"2008","unstructured":"Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B. & Olanow, C. W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson\u2019s disease. Nat. Med. 14, 504\u2013506 (2008).","journal-title":"Nat. Med."},{"key":"155_CR38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","volume":"72","author":"LA Volpicelli-Daley","year":"2011","unstructured":"Volpicelli-Daley, L. A. et al. Exogenous \u03b1-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57\u201371 (2011).","journal-title":"Neuron"},{"key":"155_CR39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.nbd.2015.06.003","volume":"82","author":"KL Paumier","year":"2015","unstructured":"Paumier, K. L. et al. Intrastriatal injection of pre-formed mouse \u03b1-synuclein fibrils into rats triggers \u03b1-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiol. Dis. 82, 185\u2013199 (2015).","journal-title":"Neurobiol. Dis."},{"key":"155_CR40","doi-asserted-by":"crossref","first-page":"aah3374","DOI":"10.1126\/science.aah3374","volume":"353","author":"X Mao","year":"2016","unstructured":"Mao, X. et al. Pathological \u03b1-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353, aah3374 (2016).","journal-title":"Science"},{"key":"155_CR41","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","volume":"46","author":"E Masliah","year":"2005","unstructured":"Masliah, E. et al. Effects of \u03b1-synuclein immunization in a mouse model of Parkinson\u2019s disease. Neuron 46, 857\u2013868 (2005).","journal-title":"Neuron"},{"key":"155_CR42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019338","volume":"6","author":"E Masliah","year":"2011","unstructured":"Masliah, E. et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of lewy body disease. PLOS ONE 6, e19338 (2011).","journal-title":"PLOS ONE"},{"key":"155_CR43","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","volume":"32","author":"E-J Bae","year":"2012","unstructured":"Bae, E.-J. et al. Antibody-aided clearance of extracellular -synuclein prevents cell-to-cell aggregate transmission. J. Neurosci. 32, 13454\u201313469 (2012).","journal-title":"J. Neurosci."},{"key":"155_CR44","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","volume":"127","author":"M Mandler","year":"2014","unstructured":"Mandler, M. et al. Next-generation active immunization approach for synucleinopathies: Implications for Parkinson\u2019s disease clinical trials. Acta Neuropathol. 127, 861\u2013879 (2014).","journal-title":"Acta Neuropathol."},{"key":"155_CR45","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","volume":"75","author":"J Jankovic","year":"2018","unstructured":"Jankovic, J. et al. Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti\u2014synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurol. 75, 1206\u20131214 (2018).","journal-title":"JAMA Neurol."},{"key":"155_CR46","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/mds.26377","volume":"31","author":"A Schneeberger","year":"2016","unstructured":"Schneeberger, A., Tierney, L. & Mandler, M. Active immunization therapies for Parkinson\u2019s disease and multiple system atrophy. Mov. Disord. 31, 214\u2013224 (2016).","journal-title":"Mov. Disord."},{"key":"155_CR47","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mds.24962","volume":"27","author":"M Poulopoulos","year":"2012","unstructured":"Poulopoulos, M., Levy, O. A. & Alcalay, R. N. The neuropathology of genetic Parkinson\u2019s disease. Mov. Disord. 27, 831\u2013842 (2012).","journal-title":"Mov. Disord."},{"key":"155_CR48","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/jamaneurol.2013.172","volume":"70","author":"KM Doherty","year":"2013","unstructured":"Doherty, K. M. et al. Parkin disease: a clinicopathologic entity? JAMA Neurol. 70, 571\u2013579 (2013).","journal-title":"JAMA Neurol."},{"issue":"Suppl. 1","key":"155_CR49","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/jnc.13517","volume":"139","author":"J Blanz","year":"2016","unstructured":"Blanz, J. & Saftig, P. Parkinson\u2019s disease: acid-glucocerebrosidase activity and alpha-synuclein clearance. J. Neurochem. 139 (Suppl. 1), 198\u2013215 (2016).","journal-title":"J. Neurochem."},{"key":"155_CR50","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neurobiolaging.2009.05.019","volume":"32","author":"R Frigerio","year":"2011","unstructured":"Frigerio, R. et al. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol. Aging 32, 857\u2013863 (2011).","journal-title":"Neurobiol. Aging"},{"key":"155_CR51","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.expneurol.2017.07.019","volume":"298","author":"AB West","year":"2017","unstructured":"West, A. B. Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease. Exp. Neurol. 298, 236\u2013245 (2017).","journal-title":"Exp. Neurol."},{"key":"155_CR52","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ng.485","volume":"41","author":"W Satake","year":"2009","unstructured":"Satake, W. et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson\u2019s disease. Nat. Genet. 41, 1303\u20131307 (2009).","journal-title":"Nat. Genet."},{"key":"155_CR53","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/ng.487","volume":"41","author":"J Sim\u00f3n-S\u00e1nchez","year":"2009","unstructured":"Sim\u00f3n-S\u00e1nchez, J. et al. Genome-wide association study reveals genetic risk underlying Parkinson\u2019s disease. Nat. Genet. 41, 1308\u20131312 (2009).","journal-title":"Nat. Genet."},{"key":"155_CR54","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ng.3043","volume":"46","author":"MA Nalls","year":"2014","unstructured":"Nalls, M. A. et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson\u2019s disease. Nat. Genet. 46, 989\u2013993 (2014).","journal-title":"Nat. Genet."},{"key":"155_CR55","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/jnc.12949","volume":"131","author":"I Martin","year":"2014","unstructured":"Martin, I., Kim, J. W., Dawson, V. L. & Dawson, T. M. LRRK2 pathobiology in Parkinson\u2019s disease. J. Neurochem. 131, 554\u2013565 (2014).","journal-title":"J. Neurochem."},{"key":"155_CR56","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.expneurol.2014.05.025","volume":"261","author":"AR Esteves","year":"2014","unstructured":"Esteves, A. R., Swerdlow, R. H. & Cardoso, S. M. LRRK2, a puzzling protein: insights into Parkinson\u2019s disease pathogenesis. Exp. Neurol. 261, 206\u2013216 (2014).","journal-title":"Exp. Neurol."},{"key":"155_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.14182","author":"N Cresto","year":"2018","unstructured":"Cresto, N. et al. The unlikely partnership between LRRK2 and \u03b1-synuclein in Parkinson\u2019s disease. Eur. J. Neurosci. https:\/\/doi.org\/10.1111\/ejn.14182 (2018).","journal-title":"Eur. J. Neurosci."},{"key":"155_CR58","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40478-018-0550-0","volume":"6","author":"MX Henderson","year":"2018","unstructured":"Henderson, M. X., Peng, C., Trojanowski, J. Q. & Lee, V. M. Y. LRRK2 activity does not dramatically alter \u03b1-synuclein pathology in primary neurons. Acta Neuropathol. Commun. 6, 45 (2018).","journal-title":"Acta Neuropathol. Commun."},{"key":"155_CR59","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","volume":"7","author":"DG Healy","year":"2008","unstructured":"Healy, D. G. et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson\u2019s disease: a case-control study. Lancet Neurol. 7, 583\u2013590 (2008).","journal-title":"Lancet Neurol."},{"key":"155_CR60","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/mds.27414","volume":"33","author":"SP Sardi","year":"2018","unstructured":"Sardi, S. P., Cedarbaum, J. M. & Brundin, P. Targeted therapies for Parkinson\u2019s disease: from genetics to the clinic. Mov. Disord. 33, 684\u2013696 (2018).","journal-title":"Mov. Disord."},{"key":"155_CR61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066164","volume":"8","author":"D Ness","year":"2013","unstructured":"Ness, D. et al. Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis. PLOS ONE 8, e66164 (2013).","journal-title":"PLOS ONE"},{"key":"155_CR62","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1093\/hmg\/ddr348","volume":"20","author":"MC Herzig","year":"2011","unstructured":"Herzig, M. C. et al. LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum. Mol. Genet. 20, 4209\u20134223 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"155_CR63","doi-asserted-by":"crossref","first-page":"273ra15","DOI":"10.1126\/scitranslmed.aaa3634","volume":"7","author":"RN Fuji","year":"2015","unstructured":"Fuji, R. N. et al. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci. Transl Med. 7, 273ra15 (2015).","journal-title":"Sci. Transl Med."},{"key":"155_CR64","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1042\/BCJ20170803","volume":"475","author":"Y Fan","year":"2017","unstructured":"Fan, Y. et al. Interrogating Parkinson\u2019s disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils. Biochem. J. 475, 23\u201344 (2017).","journal-title":"Biochem. J."},{"key":"155_CR65","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar5429","volume":"10","author":"R Maio Di","year":"2018","unstructured":"Di Maio, R. et al. LRRK2 activation in idiopathic Parkinson\u2019s disease. Sci. Transl Med. 10, eaar5429 (2018).","journal-title":"Sci. Transl Med."},{"key":"155_CR66","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1096-7192(03)00071-4","volume":"79","author":"N Tayebi","year":"2003","unstructured":"Tayebi, N. et al. Gaucher disease with parkinsonian manifestations: Does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol. Genet. Metab. 79, 104\u2013109 (2003).","journal-title":"Mol. Genet. Metab."},{"key":"155_CR67","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N. Engl. J. Med. 361, 1651\u20131661 (2009).","journal-title":"N. Engl. J. Med."},{"key":"155_CR68","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mds.26071","volume":"30","author":"K Brockmann","year":"2015","unstructured":"Brockmann, K. et al. GBA-associated Parkinson\u2019s disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov. Disord. 30, 407\u2013411 (2015).","journal-title":"Mov. Disord."},{"key":"155_CR69","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ymgme.2011.06.008","volume":"104","author":"JH Choi","year":"2011","unstructured":"Choi, J. H. et al. Aggregation of \u03b1-synuclein in brain samples from subjects with glucocerebrosidase mutations. Mol. Genet. Metab. 104, 185\u2013188 (2011).","journal-title":"Mol. Genet. Metab."},{"key":"155_CR70","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli, J. R. et al. Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37\u201352 (2011).","journal-title":"Cell"},{"key":"155_CR71","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bcmd.2012.10.007","volume":"50","author":"I Bendikov-Bar","year":"2013","unstructured":"Bendikov-Bar, I., Maor, G., Filocamo, M. & Horowitz, M. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol. Dis. 50, 141\u2013145 (2013).","journal-title":"Blood Cells Mol. Dis."},{"key":"155_CR72","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/bi9002265","volume":"48","author":"RL Lieberman","year":"2009","unstructured":"Lieberman, R. L., D\u2019Aquino, J. A., Ringe, D. & Petsko, G. A. Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability. Biochemistry 48, 4816\u20134827 (2009).","journal-title":"Biochemistry"},{"key":"155_CR73","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awu020","volume":"137","author":"A McNeill","year":"2014","unstructured":"McNeill, A. et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137, 1481\u20131495 (2014).","journal-title":"Brain"},{"key":"155_CR74","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1073\/pnas.1616152114","volume":"114","author":"SP Sardi","year":"2017","unstructured":"Sardi, S. P. et al. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proc. Natl Acad. Sci. USA 114, 2699\u20132704 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"155_CR75","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.pneurobio.2010.06.001","volume":"92","author":"DL Double","year":"2010","unstructured":"Double, D. L., Reyes, R., Werry, W. L. & Halliday, H. M. Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions? Prog. Neurobiol. 92, 316\u2013329 (2010).","journal-title":"Prog. Neurobiol."},{"key":"155_CR76","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrn.2016.178","volume":"18","author":"DJ Surmeier","year":"2017","unstructured":"Surmeier, D. J., Obeso, J. A. & Halliday, G. M. Selective neuronal vulnerability in Parkinson disease. Nat. Rev. Neurosci. 18, 101\u2013113 (2017).","journal-title":"Nat. Rev. Neurosci."},{"key":"155_CR77","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.cub.2015.07.050","volume":"25","author":"C Pacelli","year":"2015","unstructured":"Pacelli, C. et al. Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons. Curr. Biol. 25, 2349\u20132360 (2015).","journal-title":"Curr. Biol."},{"key":"155_CR78","doi-asserted-by":"crossref","first-page":"10736","DOI":"10.1074\/jbc.R112.410530","volume":"288","author":"DJ Surmeier","year":"2013","unstructured":"Surmeier, D. J. & Schumacker, P. T. Calcium, bioenergetics, and neuronal vulnerability in Parkinson\u2019s disease. J. Biol. Chem. 288, 10736\u201310741 (2013).","journal-title":"J. Biol. Chem."},{"key":"155_CR79","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/nn.3717","volume":"17","author":"J Sanchez-Padilla","year":"2014","unstructured":"Sanchez-Padilla, J. et al. Mitochondrial oxidant stress in locus coeruleus is regulated by activity and nitric oxide synthase. Nat. Neurosci. 17, 832\u2013840 (2014).","journal-title":"Nat. Neurosci."},{"key":"155_CR80","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nature09536","volume":"468","author":"JN Guzman","year":"2010","unstructured":"Guzman, J. N. et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468, 696\u2013700 (2010).","journal-title":"Nature"},{"key":"155_CR81","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/nn.3209","volume":"15","author":"JA Goldberg","year":"2012","unstructured":"Goldberg, J. A. et al. Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson\u2019s disease. Nat. Neurosci. 15, 1414\u20131421 (2012).","journal-title":"Nat. Neurosci."},{"key":"155_CR82","first-page":"697404","volume":"2015","author":"K Gudala","year":"2015","unstructured":"Gudala, K., Kanukula, R. & Bansal, D. Reduced risk of Parkinson\u2019s disease in users of calcium channel blockers: a meta-analysis. Int. J. Chronic Dis. 2015, 697404 (2015).","journal-title":"Int. J. Chronic Dis."},{"key":"155_CR83","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1212\/01.wnl.0000262033.01945.9a","volume":"68","author":"AE Oakley","year":"2007","unstructured":"Oakley, A. E. et al. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 68, 1820\u20131825 (2007).","journal-title":"Neurology"},{"key":"155_CR84","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(14)70117-6","volume":"13","author":"RJ Ward","year":"2014","unstructured":"Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R. & Zecca, L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 13, 1045\u20131060 (2014).","journal-title":"Lancet Neurol."},{"key":"155_CR85","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00702-010-0531-3","volume":"118","author":"DT Dexter","year":"2011","unstructured":"Dexter, D. T. et al. Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson\u2019s disease after peripheral administration. J. Neural Transm. 118, 223\u2013231 (2011).","journal-title":"J. Neural Transm."},{"key":"155_CR86","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-01402-2","volume":"7","author":"A Martin-Bastida","year":"2017","unstructured":"Martin-Bastida, A. et al. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson\u2019s disease. Sci. Rep. 7, 1398 (2017).","journal-title":"Sci. Rep."},{"key":"155_CR87","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/mds.20856","volume":"21","author":"TG Ton","year":"2006","unstructured":"Ton, T. G. et al. Nonsteroidal anti-inflammatory drugs and risk of Parkinson\u2019s disease. Mov. Disord. 21, 964\u2013969 (2006).","journal-title":"Mov. Disord."},{"key":"155_CR88","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1212\/WNL.0b013e3181d5a4a3","volume":"74","author":"JJ Gagne","year":"2010","unstructured":"Gagne, J. J. & Power, M. C. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 74, 995\u20131002 (2010).","journal-title":"Neurology"},{"key":"155_CR89","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1212\/WNL.38.8.1285","volume":"38","author":"PL McGeer","year":"1988","unstructured":"McGeer, P. L., Itagaki, S., Boyes, B. E. & McGeer, E. G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson\u2019s and Alzheimer\u2019s disease brains. Neurology 38, 1285\u20131285 (1988).","journal-title":"Neurology"},{"key":"155_CR90","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0304-3940(94)90508-8","volume":"180","author":"M Mogi","year":"1994","unstructured":"Mogi, M. et al. Interleukin-1\u03b2, interleukin-6, epidermal growth factor and transforming growth factor-\u03b1 are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180, 147\u2013150 (1994).","journal-title":"Neurosci. Lett."},{"key":"155_CR91","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","volume":"8","author":"EC Hirsch","year":"2009","unstructured":"Hirsch, E. C. & Hunot, S. Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection? Lancet Neurol. 8, 382\u2013397 (2009).","journal-title":"Lancet Neurol."},{"key":"155_CR92","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1600-0404.1999.tb00721.x","volume":"100","author":"RJ Dobbs","year":"1999","unstructured":"Dobbs, R. J. et al. Association of circulating TNF-\u03b1 and IL-6 with ageing and parkinsonism. Acta Neurol. Scand. 100, 34\u201341 (1999).","journal-title":"Acta Neurol. Scand."},{"key":"155_CR93","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0304-3940(95)12192-7","volume":"202","author":"D Blum-Degena","year":"1995","unstructured":"Blum-Degena, D. et al. Interleukin-1\u03b2 and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer\u2019s and de novo Parkinson\u2019s disease patients. Neurosci. Lett. 202, 17\u201320 (1995).","journal-title":"Neurosci. Lett."},{"key":"155_CR94","doi-asserted-by":"crossref","first-page":"a009381","DOI":"10.1101\/cshperspect.a009381","volume":"2","author":"RL Mosley","year":"2012","unstructured":"Mosley, R. L., Hutter-Saunders, J. A., Stone, D. K. & Gendelman, H. E. Inflammation and adaptive immunity in Parkinson\u2019s disease. Cold Spring Harb. Perspect. Med. 2, a009381 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"155_CR95","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1212\/01.wnl.0000279519.99344.ad","volume":"69","author":"AD Wahner","year":"2007","unstructured":"Wahner, A. D., Bronstein, J. M., Bordelon, Y. M. & Ritz, B. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 69, 1836\u20131842 (2007).","journal-title":"Neurology"},{"key":"155_CR96","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/11316780-000000000-00000","volume":"26","author":"A Samii","year":"2009","unstructured":"Samii, A., Etminan, M., Wiens, M. O. & Jafari, S. NSAID use and the risk of parkinsons disease: systematic review and meta-analysis of observational studies. Drugs Aging 26, 769\u2013779 (2009).","journal-title":"Drugs Aging"},{"key":"155_CR97","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1212\/WNL.0b013e31820f2d79","volume":"76","author":"X Gao","year":"2011","unstructured":"Gao, X., Chen, H., Schwarzschild, M. A. & Ascherio, A. Use of ibuprofen and risk of Parkinson disease. Neurology 76, 863\u2013869 (2011).","journal-title":"Neurology"},{"key":"155_CR98","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.imbio.2015.10.002","volume":"221","author":"A Shameli","year":"2016","unstructured":"Shameli, A. et al. A critical role for \u03b1-synuclein in development and function of T lymphocytes. Immunobiology 221, 333\u2013340 (2016).","journal-title":"Immunobiology"},{"key":"155_CR99","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith, T. J. et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol. 24, 3187\u20133205 (2006).","journal-title":"J. Clin. Oncol."},{"key":"155_CR100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41531-017-0013-5","volume":"3","author":"HE Gendelman","year":"2017","unstructured":"Gendelman, H. E. et al. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson\u2019s disease trial. NPJ Parkinsons Dis. 3, 10 (2017).","journal-title":"NPJ Parkinsons Dis."},{"key":"155_CR101","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00441-017-2626-8","volume":"369","author":"S Gellhaar","year":"2017","unstructured":"Gellhaar, S., Sunnemark, D., Eriksson, H., Olson, L. & Galter, D. Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson\u2019s and Alzheimer\u2019s disease. Cell Tissue Res. 369, 445\u2013454 (2017).","journal-title":"Cell Tissue Res."},{"key":"155_CR102","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ana.20338","volume":"57","author":"Y Ouchi","year":"2005","unstructured":"Ouchi, Y. et al. Microglial activation and dopamine terminal loss in early Parkinson\u2019s disease. Ann. Neurol. 57, 168\u2013175 (2005).","journal-title":"Ann. Neurol."},{"key":"155_CR103","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2005.08.002","volume":"21","author":"A Gerhard","year":"2006","unstructured":"Gerhard, A. et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson\u2019s disease. Neurobiol. Dis. 21, 404\u2013412 (2006).","journal-title":"Neurobiol. Dis."},{"issue":"Suppl. 1","key":"155_CR104","first-page":"698","volume":"29","author":"JA Posener","year":"2014","unstructured":"Posener, J. A. et al. Safety, tolerability, and pharmacodynamics of AZD3241, a myeloperoxidase inhibitor, in Parkinson\u2019s disease [abstract]. Mov. Disord. 29 (Suppl. 1), 698 (2014).","journal-title":"Mov. Disord."},{"key":"155_CR105","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1093\/brain\/awv184","volume":"138","author":"A Jucaite","year":"2015","unstructured":"Jucaite, A. et al. Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson\u2019s disease. Brain 138, 2687\u20132700 (2015).","journal-title":"Brain"},{"key":"155_CR106","doi-asserted-by":"crossref","DOI":"10.1186\/1742-2094-5-19","volume":"5","author":"A Harkavyi","year":"2008","unstructured":"Harkavyi, A. et al. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson\u2019s disease. J. Neuroinflammation 5, 19 (2008).","journal-title":"J. Neuroinflammation"},{"key":"155_CR107","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","volume":"21","author":"D Athauda","year":"2016","unstructured":"Athauda, D. & Foltynie, T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: mechanisms of action. Drug Discov. Today 21, 802\u2013818 (2016).","journal-title":"Drug Discov. Today"},{"key":"155_CR108","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda, D. et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390, 1664\u20131675 (2017).","journal-title":"Lancet"},{"key":"155_CR109","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1089\/ars.2012.4774","volume":"20","author":"F Yin","year":"2014","unstructured":"Yin, F., Boveris, A. & Cadenas, E. Mitochondrial energy metabolism and redox signaling in brain aging and neurodegeneration. Antioxid. Redox Signal. 20, 353\u2013371 (2014).","journal-title":"Antioxid. Redox Signal."},{"key":"155_CR110","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1089\/ars.2010.3779","volume":"14","author":"G Twig","year":"2011","unstructured":"Twig, G. & Shirihai, O. S. The interplay between mitochondrial dynamics and mitophagy. Antioxid. Redox Signal. 14, 1939\u20131951 (2011).","journal-title":"Antioxid. Redox Signal."},{"key":"155_CR111","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm.3983","volume":"22","author":"W Wang","year":"2016","unstructured":"Wang, W. et al. Parkinson\u2019s disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes. Nat. Med. 22, 54\u201363 (2016).","journal-title":"Nat. Med."},{"key":"155_CR112","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s11064-014-1377-0","volume":"40","author":"JC Corona","year":"2014","unstructured":"Corona, J. C. & Duchen, M. R. PPAR\u03b3 and PGC-1\u03b1 as therapeutic targets in Parkinson\u2019s. Neurochem. Res. 40, 308\u2013316 (2014).","journal-title":"Neurochem. Res."},{"key":"155_CR113","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13024-016-0090-7","volume":"11","author":"M Pinto","year":"2016","unstructured":"Pinto, M. et al. Pioglitazone ameliorates the phenotype of a novel Parkinson\u2019s disease mouse model by reducing neuroinflammation. Mol. Neurodegener. 11, 25 (2016).","journal-title":"Mol. Neurodegener."},{"key":"155_CR114","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(15)00144-1","volume":"14","author":"T Simuni","year":"2015","unstructured":"Simuni, T. et al. Pioglitazone in early Parkinson\u2019s disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 14, 795\u2013803 (2015).","journal-title":"Lancet Neurol."},{"key":"155_CR115","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.20663","volume":"58","author":"LML Lau De","year":"2005","unstructured":"De Lau, L. M. L., Koudstaal, P. J., Hofman, A. & Breteler, M. M. B. Serum uric acid levels and the risk of Parkinson disease. Ann. Neurol. 58, 797\u2013800 (2005).","journal-title":"Ann. Neurol."},{"key":"155_CR116","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/aje\/kwm127","volume":"166","author":"MG Weisskopf","year":"2007","unstructured":"Weisskopf, M. G., O\u2019Reilly, E., Chen, H., Schwarzschild, M. A. & Ascherio, A. Plasma urate and risk of Parkinson\u2019s disease. Am. J. Epidemiol. 166, 561\u2013567 (2007).","journal-title":"Am. J. Epidemiol."},{"key":"155_CR117","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/jnc.12038","volume":"123","author":"L Gong","year":"2012","unstructured":"Gong, L. et al. Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson\u2019s disease: linking to Akt\/GSK3\u03b2 signaling pathway. J. Neurochem. 123, 876\u2013885 (2012).","journal-title":"J. Neurochem."},{"key":"155_CR118","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jamaneurol.2013.5528","volume":"71","author":"MA Schwarzschild","year":"2014","unstructured":"Schwarzschild, M. A. et al. Inosine to increase serum and cerebrospinal fluid urate in parkinson disease a randomized clinical trial. JAMA Neurol. 71, 141\u2013150 (2014).","journal-title":"JAMA Neurol."},{"key":"155_CR119","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ana.22361","volume":"69","author":"RC Helmich","year":"2011","unstructured":"Helmich, R. C., Janssen, M. J. R., Oyen, W. J. G., Bloem, B. R. & Toni, I. Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Ann. Neurol. 69, 269\u2013281 (2011).","journal-title":"Ann. Neurol."},{"key":"155_CR120","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1212\/01.WNL.0000031424.51127.2B","volume":"60","author":"M Doder","year":"2003","unstructured":"Doder, M., Rabiner, E. A., Turjanski, N., Lees, A. J. & Brooks, D. J. Tremor in Parkinson\u2019s disease and serotonergic dysfunction: An11C-WAY 100635 PET study. Neurology 60, 601\u2013605 (2003).","journal-title":"Neurology"},{"key":"155_CR121","first-page":"CD003735","volume":"2","author":"R Katzenschlager","year":"2002","unstructured":"Katzenschlager, R., Sampaio, C., Costa, J. & Lees, A. Anticholinergics for symptomatic management of Parkinson\u2019s disease. Cochrane Database Syst. Rev. 2, CD003735 (2002).","journal-title":"Cochrane Database Syst. Rev."},{"key":"155_CR122","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1212\/WNL.48.4.1077","volume":"48","author":"JH Friedman","year":"1997","unstructured":"Friedman, J. H. et al. Benztropine versus clozapine for the treatment of tremor in Parkinson\u2019s disease. Neurology 48, 1077\u20131081 (1997).","journal-title":"Neurology"},{"key":"155_CR123","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/WNF.0b013e3181c47168","volume":"33","author":"AA Thomas","year":"2010","unstructured":"Thomas, A. A. & Friedman, J. H. Current use of clozapine in Parkinson disease and related disorders. Clin. Neuropharmacol. 33, 14\u201316 (2010).","journal-title":"Clin. Neuropharmacol."},{"key":"155_CR124","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/mdc3.12266","volume":"3","author":"TK Yaw","year":"2016","unstructured":"Yaw, T. K., Fox, S. H. & Lang, A. E. Clozapine in Parkinsonian rest tremor: a review of outcomes, adverse reactions, and possible mechanisms of action. Mov. Disord. Clin. Pract. 3, 116\u2013124 (2016).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"155_CR125","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/ana.410160412","volume":"16","author":"NL Foster","year":"1984","unstructured":"Foster, N. L. et al. Peripheral beta-adrenergic blockade treatment of parkinsonian tremor. Ann. Neurol. 16, 505\u2013508 (1984).","journal-title":"Ann. Neurol."},{"key":"155_CR126","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly, B. S. & Lang, A. E. Pharmacological treatment of Parkinson disease: a review. JAMA 311, 1670\u20131683 (2014).","journal-title":"JAMA"},{"key":"155_CR127","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/ana.24778","volume":"80","author":"AH Snijders","year":"2016","unstructured":"Snijders, A. H. et al. Physiology of freezing of gait. Ann. Neurol. 80, 644\u2013659 (2016).","journal-title":"Ann. Neurol."},{"key":"155_CR128","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1474-4422(15)00389-0","volume":"15","author":"EJ Henderson","year":"2016","unstructured":"Henderson, E. J. et al. Rivastigmine for gait stability in patients with Parkinson\u2019s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 15, 249\u2013258 (2016).","journal-title":"Lancet Neurol."},{"key":"155_CR129","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1212\/WNL.0b013e3181f6128c","volume":"75","author":"KA Chung","year":"2010","unstructured":"Chung, K. A., Lobb, B. M., Nutt, J. G. & Horak, F. B. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 75, 1263\u20131269 (2010).","journal-title":"Neurology"},{"key":"155_CR130","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1474-4422(12)70106-0","volume":"11","author":"C Moreau","year":"2012","unstructured":"Moreau, C. et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson\u2019s disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol. 11, 589\u2013596 (2012).","journal-title":"Lancet Neurol."},{"key":"155_CR131","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog, J. E. & Muenter, M. D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16, 448\u2013458 (2001).","journal-title":"Mov. Disord."},{"key":"155_CR132","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.expneurol.2010.07.011","volume":"225","author":"RA Hodgson","year":"2010","unstructured":"Hodgson, R. A. et al. Preladenant, a selective A2Areceptor antagonist, is active in primate models of movement disorders. Exp. Neurol. 225, 384\u2013390 (2010).","journal-title":"Exp. Neurol."},{"issue":"Suppl. 10","key":"155_CR133","doi-asserted-by":"crossref","first-page":"P7.087","DOI":"10.1212\/WNL.82.10_supplement.P7.087","volume":"82","author":"R Hauser","year":"2014","unstructured":"Hauser, R. et al. Phase-3 clinical trials of adjunctive therapy with preladenant, an adenosine 2a antagonist, in patients with Parkinson\u2019s disease [abstract]. Neurology 82 (Suppl. 10), P7.087 (2014).","journal-title":"Neurology"},{"key":"155_CR134","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/jamaneurol.2015.2268","volume":"72","author":"RA Hauser","year":"2015","unstructured":"Hauser, R. A. et al. Preladenant as an adjunctive therapy with levodopa in Parkinson disease: two randomized clinical trials and lessons learned. JAMA Neurol. 72, 1491\u20131500 (2015).","journal-title":"JAMA Neurol."},{"key":"155_CR135","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1212\/WNL.0000000000004003","volume":"88","author":"F Stocchi","year":"2017","unstructured":"Stocchi, F. et al. Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease. Neurology 88, 2198\u20132206 (2017).","journal-title":"Neurology"},{"key":"155_CR136","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.parkreldis.2009.06.008","volume":"16","author":"HH Fernandez","year":"2010","unstructured":"Fernandez, H. H. et al. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkonsonism Relat. Disord. 16, 16\u201320 (2010).","journal-title":"Parkonsonism Relat. Disord."},{"key":"155_CR137","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.21315","volume":"63","author":"PA LeWitt","year":"2008","unstructured":"LeWitt, P. A. et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces off time in Parkinson\u2019s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann. Neurol. 63, 295\u2013302 (2008).","journal-title":"Ann. Neurol."},{"key":"155_CR138","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/mds.22095","volume":"23","author":"RA Hauser","year":"2008","unstructured":"Hauser, R. A. et al. Study of istradefylline in patients with Parkinson\u2019s disease on levodopa with motor fluctuations. Mov. Disord. 23, 2177\u20132185 (2008).","journal-title":"Mov. Disord."},{"key":"155_CR139","volume":"7","author":"W Sako","year":"2017","unstructured":"Sako, W., Murakami, N., Motohama, K., Izumi, Y. & Kaji, R. The effect of istradefylline for Parkinson\u2019s disease: a meta-analysis. Sci. Rep. 7, 18018 (2017).","journal-title":"Sci. Rep."},{"key":"155_CR140","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1002\/mds.22792","volume":"25","author":"M Carta","year":"2010","unstructured":"Carta, M., Carlsson, T., Mu\u00f1oz, A., Kirik, D. & Bj\u00f6rklund, A. Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson\u2019s disease. Mov. Disord. 25, S174\u2013179 (2010).","journal-title":"Mov. Disord."},{"key":"155_CR141","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1212\/WNL.57.10.1829","volume":"57","author":"F Bibbiani","year":"2001","unstructured":"Bibbiani, F., Oh, J. D. & Chase, T. N. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57, 1829\u20131834 (2001).","journal-title":"Neurology"},{"key":"155_CR142","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I","volume":"15","author":"E Luginger","year":"2000","unstructured":"Luginger, E., Wenning, G., B\u00f6sch, S. & Poewe, W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson\u2019s disease. Mov. Disord. 15, 873\u2013878 (2000).","journal-title":"Mov. Disord."},{"key":"155_CR143","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/mds.27261","volume":"33","author":"B Picconi","year":"2018","unstructured":"Picconi, B., Hern\u00e1ndez, L. F., Obeso, J. A. & Calabresi, P. Motor complications in Parkinson\u2019s disease: striatal molecular and electrophysiological mechanisms of dyskinesias. Mov. Disord. 33, 867\u2013876 (2018).","journal-title":"Mov. Disord."},{"key":"155_CR144","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nbd.2011.09.014","volume":"48","author":"TB Lentz","year":"2012","unstructured":"Lentz, T. B., Gray, S. J. & Samulski, R. J. Viral vectors for gene delivery to the central nervous system. Neurobiol. Dis. 48, 179\u2013188 (2012).","journal-title":"Neurobiol. Dis."},{"key":"155_CR145","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","volume":"70","author":"JL Eberling","year":"2008","unstructured":"Eberling, J. L. et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70, 1980\u20131983 (2008).","journal-title":"Neurology"},{"key":"155_CR146","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","volume":"10","author":"PA LeWitt","year":"2011","unstructured":"LeWitt, P. A. et al. AAV2-GAD gene therapy for advanced Parkinson\u2019s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 10, 309\u2013319 (2011).","journal-title":"Lancet Neurol."},{"key":"155_CR147","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","volume":"73","author":"CW Christine","year":"2009","unstructured":"Christine, C. W. et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73, 1662\u20131669 (2009).","journal-title":"Neurology"},{"key":"155_CR148","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1006\/mthe.2001.0466","volume":"4","author":"R S\u00e1nchez-Pernaute","year":"2001","unstructured":"S\u00e1nchez-Pernaute, R., Harvey-White, J., Cunningham, J. & Bankiewicz, K. S. Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. Mol. Ther. 4, 324\u2013330 (2001).","journal-title":"Mol. Ther."},{"key":"155_CR149","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1089\/hum.1998.9.17-2527","volume":"9","author":"D-S Fan","year":"1998","unstructured":"Fan, D.-S. et al. Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum. Gene Ther. 9, 2527\u20132535 (1998).","journal-title":"Hum. Gene Ther."},{"key":"155_CR150","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/ana.25331","volume":"84","author":"CW Christine","year":"2018","unstructured":"Christine, C. W. et al. VY-AADC01 in medically refractory Parkinson\u2019s disease: safety and efficacy of a phase 1b dose-ranging study 12 months and beyond [abstract]. Ann. Neurol. 84, S1\u2013S280 (2018).","journal-title":"Ann. Neurol."},{"key":"155_CR151","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.jcbfm.9600364","volume":"27","author":"ME Emborg","year":"2007","unstructured":"Emborg, M. E. et al. Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J. Cereb. Blood Flow Metab. 27, 501\u2013509 (2007).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"155_CR152","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90133","volume":"2","author":"M Niethammer","year":"2017","unstructured":"Niethammer, M. et al. Long-term follow-up of a randomized AAV2- GAD gene therapy trial for Parkinson\u2019s disease. JCI Insight 2, e90133 (2017).","journal-title":"JCI Insight"},{"key":"155_CR153","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1046\/j.1460-9568.1999.00566.x","volume":"11","author":"C Rosenblad","year":"1999","unstructured":"Rosenblad, C. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson\u2019s disease after administration into the striatum or the lateral ventricle. Eur. J. Neurosci. 11, 1554\u20131566 (1999).","journal-title":"Eur. J. Neurosci."},{"key":"155_CR154","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1097\/00001756-199906030-00029","volume":"10","author":"C Rosenblad","year":"1999","unstructured":"Rosenblad, C., Kirik, D. & Bjorklund, A. Neurturin enhances the survival of intrastriatal fetal dopaminergic transplants. Neuroreport 10, 1783\u20131787 (1999).","journal-title":"Neuroreport"},{"key":"155_CR155","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1126\/science.8493557","volume":"260","author":"LFH Lin","year":"1993","unstructured":"Lin, L. F. H., Doherty, D. H., Lile, J. D., Bektesh, S. & Collins, F. GDNF: a glial cell line - derived neurotrophic factor for midbrain dopaminergic neurons. Science 260, 1130\u20131132 (1993).","journal-title":"Science"},{"key":"155_CR156","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ana.410420212","volume":"42","author":"Y Miyoshi","year":"1997","unstructured":"Miyoshi, Y. et al. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. Ann. Neurol. 42, 208\u2013214 (1997).","journal-title":"Ann. Neurol."},{"key":"155_CR157","first-page":"1396","volume":"282","author":"Z Zhang","year":"1997","unstructured":"Zhang, Z. et al. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J. Pharmacol. Exp. Ther. 282, 1396\u20131401 (1997).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"155_CR158","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/384467a0","volume":"384","author":"PT Kotzbauer","year":"1996","unstructured":"Kotzbauer, P. T. et al. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 384, 467\u2013470 (1996).","journal-title":"Nature"},{"key":"155_CR159","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nbd.2007.04.003","volume":"27","author":"M Gasmi","year":"2007","unstructured":"Gasmi, M. et al. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson\u2019s disease. Neurobiol. Dis. 27, 67\u201376 (2007).","journal-title":"Neurobiol. Dis."},{"key":"155_CR160","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/mds.21503","volume":"22","author":"CD Herzog","year":"2007","unstructured":"Herzog, C. D. et al. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov. Disord. 22, 1124\u20131132 (2007).","journal-title":"Mov. Disord."},{"key":"155_CR161","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ana.21032","volume":"60","author":"JH Kordower","year":"2006","unstructured":"Kordower, J. H. et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann. Neurol. 60, 706\u2013715 (2006).","journal-title":"Ann. Neurol."},{"key":"155_CR162","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","volume":"7","author":"WJ Marks","year":"2008","unstructured":"Marks, W. J. et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson\u2019s disease: an open-label, phase I trial. Lancet Neurol. 7, 400\u2013408 (2008).","journal-title":"Lancet Neurol."},{"key":"155_CR163","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","volume":"9","author":"WJ Marks","year":"2010","unstructured":"Marks, W. J. et al. Gene delivery of AAV2-neurturin for Parkinson\u2019s disease: a double-blind, randomised, controlled trial. Lancet Neurol. 9, 1164\u20131172 (2010).","journal-title":"Lancet Neurol."},{"key":"155_CR164","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nature05957","volume":"448","author":"P Lindholm","year":"2007","unstructured":"Lindholm, P. et al. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 448, 73\u201377 (2007).","journal-title":"Nature"},{"key":"155_CR165","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1227\/00006123-199510000-00018","volume":"37","author":"T Tsukahara","year":"1995","unstructured":"Tsukahara, T., Takeda, M., Shimohama, S., Ohara, O. & Hashimoto, N. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Neurosurgery 37, 733\u2013741 (1995).","journal-title":"Neurosurgery"},{"key":"155_CR166","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/j.1460-9568.2004.03254.x","volume":"19","author":"T Yasuhara","year":"2004","unstructured":"Yasuhara, T. et al. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson\u2019s disease. Eur. J. Neurosci. 19, 1494\u20131504 (2004).","journal-title":"Eur. J. Neurosci."},{"key":"155_CR167","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nrneurol.2015.123","volume":"11","author":"RA Barker","year":"2015","unstructured":"Barker, R. A., Drouin-Ouellet, J. & Parmar, M. Cell-based therapies for Parkinson disease-past insights and future potential. Nat. Rev. Neurol. 11, 492\u2013503 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"155_CR168","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1474-4422(12)70295-8","volume":"12","author":"RA Barker","year":"2013","unstructured":"Barker, R. A., Barrett, J., Mason, S. L. & Bj\u00f6rklund, A. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson\u2019s disease. Lancet Neurol. 12, 85\u201391 (2013).","journal-title":"Lancet Neurol."},{"key":"155_CR169","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1126\/science.2105529","volume":"247","author":"O Lindvall","year":"1990","unstructured":"Lindvall, O. et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson\u2019s disease. Science 247, 574\u2013577 (1990).","journal-title":"Science"},{"key":"155_CR170","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/ana.10359","volume":"52","author":"Y Ma","year":"2002","unstructured":"Ma, Y. et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann. Neurol. 52, 628\u2013634 (2002).","journal-title":"Ann. Neurol."},{"key":"155_CR171","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200103083441002","volume":"344","author":"CR Freed","year":"2001","unstructured":"Freed, C. R. et al. Transplantation of embryonic dopamine neurons for severe Parkinson\u2019s disease. N. Engl. J. Med. 344, 710\u2013719 (2001).","journal-title":"N. Engl. J. Med."},{"key":"155_CR172","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.10720","volume":"54","author":"CW Olanow","year":"2003","unstructured":"Olanow, C. W. et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson\u2019s disease. Ann. Neurol. 54, 403\u2013414 (2003).","journal-title":"Ann. Neurol."},{"key":"155_CR173","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/nm1495","volume":"12","author":"NS Roy","year":"2006","unstructured":"Roy, N. S. et al. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat. Med. 12, 1259\u20131268 (2006).","journal-title":"Nat. Med."},{"key":"155_CR174","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature10648","volume":"480","author":"S Kriks","year":"2011","unstructured":"Kriks, S. et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson\u2019s disease. Nature 480, 547\u2013551 (2011).","journal-title":"Nature"},{"key":"155_CR175","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.stem.2014.09.017","volume":"15","author":"S Grealish","year":"2014","unstructured":"Grealish, S. et al. Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson\u2019s disease. Cell Stem Cell 15, 653\u2013665 (2014).","journal-title":"Cell Stem Cell"},{"key":"155_CR176","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663\u2013676 (2006).","journal-title":"Cell"},{"key":"155_CR177","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nature23664","volume":"548","author":"T Kikuchi","year":"2017","unstructured":"Kikuchi, T. et al. Human iPS cell-derived dopaminergic neurons function in a primate Parkinson\u2019s disease model. Nature 548, 592\u2013596 (2017).","journal-title":"Nature"},{"key":"155_CR178","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.stem.2017.09.014","volume":"21","author":"RA Barker","year":"2017","unstructured":"Barker, R. A., Parmar, M., Studer, L. & Takahashi, J. Human trials of stem cell-derived dopamine neurons for Parkinson\u2019s disease: dawn of a new era. Cell Stem Cell 21, 569\u2013573 (2017).","journal-title":"Cell Stem Cell"},{"key":"155_CR179","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03119636 (2017)."},{"key":"155_CR180","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1056\/NEJMp1408779","volume":"371","author":"MS Okun","year":"2014","unstructured":"Okun, M. S. Deep-brain stimulation \u2014 entering the era of human neural-network modulation. N. Engl. J. Med. 371, 1369\u20131373 (2014).","journal-title":"N. Engl. J. Med."},{"key":"155_CR181","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1474-4422(10)70093-4","volume":"9","author":"A Williams","year":"2010","unstructured":"Williams, A. et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson\u2019s disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol. 9, 581\u2013591 (2010).","journal-title":"Lancet Neurol."},{"key":"155_CR182","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2008.929","volume":"301","author":"FM Weaver","year":"2009","unstructured":"Weaver, F. M. et al. Bilateral deep brain stimulation versus best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 301, 63\u201373 (2009).","journal-title":"JAMA"},{"key":"155_CR183","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/ana.21596","volume":"65","author":"MS Okun","year":"2009","unstructured":"Okun, M. S. et al. Cognition and mood in Parkinson\u2019s disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann. Neurol. 65, 586\u2013595 (2009).","journal-title":"Ann. Neurol."},{"key":"155_CR184","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa060281","volume":"355","author":"G Deuschl","year":"2006","unstructured":"Deuschl, G. et al. A randomized trial of deep-brain stimulation for Parkinson\u2019s disease. N. Engl. J. Med. 355, 896\u2013908 (2006).","journal-title":"N. Engl. J. Med."},{"key":"155_CR185","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1056\/NEJMoa0907083","volume":"362","author":"KA Follett","year":"2010","unstructured":"Follett, K. A. et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson\u2019s disease. N. Engl. J. Med. 362, 2077\u20132091 (2010).","journal-title":"N. Engl. J. Med."},{"key":"155_CR186","doi-asserted-by":"crossref","first-page":"11986","DOI":"10.1523\/JNEUROSCI.1568-13.2013","volume":"33","author":"D Grabli","year":"2013","unstructured":"Grabli, D. et al. Gait disorders in parkinsonian monkeys with pedunculopontine nucleus lesions: a tale of two systems. J. Neurosci. 33, 11986\u201311993 (2013).","journal-title":"J. Neurosci."},{"key":"155_CR187","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fnins.2016.00173","volume":"10","author":"P Hickey","year":"2016","unstructured":"Hickey, P. & Stacy, M. Deep brain stimulation: a paradigm shifting approach to treat Parkinson\u2019s disease. Front. Neurosci. 10, 173 (2016).","journal-title":"Front. Neurosci."},{"key":"155_CR188","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1097\/00001756-200412030-00012","volume":"15","author":"N Jenkinson","year":"2004","unstructured":"Jenkinson, N., Nandi, D., Miall, R. C., Stein, J. F. & Aziz, T. Z. Pedunculopontine nucleus stimulation improves akinesia in a Parkinsonian monkey. Neuroreport 15, 2621\u20132624 (2004).","journal-title":"Neuroreport"},{"key":"155_CR189","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/brain\/awl346","volume":"130","author":"A Stefani","year":"2007","unstructured":"Stefani, A. et al. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson\u2019s disease. Brain 130, 1596\u20131607 (2007).","journal-title":"Brain"},{"key":"155_CR190","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1097\/01.wnr.0000187637.20771.a0","volume":"16","author":"P Plaha","year":"2005","unstructured":"Plaha, P. & Gill, S. S. Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson\u2019s disease. Neuroreport 16, 1883\u20131887 (2005).","journal-title":"Neuroreport"},{"key":"155_CR191","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/brain\/awn294","volume":"132","author":"N Chastan","year":"2009","unstructured":"Chastan, N. et al. Effects of nigral stimulation on locomotion and postural stability in patients with Parkinson\u2019s disease. Brain 132, 172\u2013184 (2009).","journal-title":"Brain"},{"key":"155_CR192","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/brain\/awt122","volume":"136","author":"D Weiss","year":"2013","unstructured":"Weiss, D. et al. Nigral stimulation for resistant axial motor impairment in Parkinson\u2019s disease? A randomized controlled trial. Brain 136, 2098\u20132108 (2013).","journal-title":"Brain"},{"key":"155_CR193","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/mds.26376","volume":"30","author":"EJ Quinn","year":"2015","unstructured":"Quinn, E. J. et al. Beta oscillations in freely moving Parkinson\u2019s subjects are attenuated during deep brain stimulation. Mov. Disord. 30, 1750\u20131758 (2015).","journal-title":"Mov. Disord."},{"key":"155_CR194","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.cell.2017.05.024","volume":"169","author":"N Grossman","year":"2017","unstructured":"Grossman, N. et al. Noninvasive deep brain stimulation via temporally interfering electric fields. Cell 169, 1029\u20131041 (2017).","journal-title":"Cell"},{"key":"155_CR195","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1126\/science.aau4916","volume":"361","author":"A Gittis","year":"2018","unstructured":"Gittis, A. Probing new targets for movement disorders. Science 361, 462 (2018).","journal-title":"Science"},{"key":"155_CR196","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1126\/science.aaq1144","volume":"359","author":"S Chen","year":"2018","unstructured":"Chen, S. et al. Near-infrared deep brain stimulation via upconversion nanoparticle\u2013mediated optogenetics. Science 359, 679\u2013684 (2018).","journal-title":"Science"},{"key":"155_CR197","volume":"7","author":"DL Fischer","year":"2017","unstructured":"Fischer, D. L. et al. Subthalamic nucleus deep brain stimulation does not modify the functional deficits or axonopathy induced by nigrostriatal \u03b1-synuclein overexpression. Sci. Rep. 7, 16356 (2017).","journal-title":"Sci. Rep."},{"key":"155_CR198","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.3171\/2016.2.JNS151988","volume":"126","author":"CG Horne van","year":"2017","unstructured":"van Horne, C. G. et al. Implantation of autologous peripheral nerve grafts into the substantia nigra of subjects with idiopathic Parkinson\u2019s disease treated with bilateral STN DBS: a report of safety and feasibility. J. Neurosurg. 126, 1140\u20131147 (2017).","journal-title":"J. Neurosurg."},{"key":"155_CR199","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol. Aging"},{"key":"155_CR200","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/brain\/awt224","volume":"136","author":"H Mortiboys","year":"2013","unstructured":"Mortiboys, H., Aasly, J. & Bandmann, O. Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson\u2019s disease. Brain 136, 3038\u20133050 (2013).","journal-title":"Brain"},{"key":"155_CR201","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/nature04788","volume":"441","author":"J Park","year":"2006","unstructured":"Park, J. et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441, 1157\u20131161 (2006).","journal-title":"Nature"},{"key":"155_CR202","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/nn.2372","volume":"12","author":"LS Tain","year":"2009","unstructured":"Tain, L. S. et al. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat. Neurosci. 12, 1129\u20131135 (2009).","journal-title":"Nat. Neurosci."},{"key":"155_CR203","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/nature04779","volume":"441","author":"IE Clark","year":"2006","unstructured":"Clark, I. E. et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441, 1162\u20131166 (2006).","journal-title":"Nature"},{"key":"155_CR204","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2014.12.007","volume":"85","author":"AM Pickrell","year":"2015","unstructured":"Pickrell, A. M. & Youle, R. J. The roles of PINK1, Parkin, and mitochondrial fidelity in parkinson\u2019s disease. Neuron 85, 257\u2013273 (2015).","journal-title":"Neuron"},{"key":"155_CR205","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cell.2011.02.010","volume":"144","author":"JH Shin","year":"2011","unstructured":"Shin, J. H. et al. PARIS (ZNF746) repression of PGC-1\u03b1 contributes to neurodegeneration in parkinson\u2019s disease. Cell 144, 689\u2013702 (2011).","journal-title":"Cell"},{"key":"155_CR206","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1093\/hmg\/ddt068","volume":"22","author":"D Ottolini","year":"2013","unstructured":"Ottolini, D., Cal\u00ec, T., Negro, A. & Brini, M. The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering. Hum. Mol. Genet. 22, 2152\u20132168 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"155_CR207","doi-asserted-by":"crossref","first-page":"E187","DOI":"10.3390\/md14100187","volume":"14","author":"CW Feng","year":"2016","unstructured":"Feng, C. W. et al. Neuroprotective effect of the marine-derived compound 11-dehydrosinulariolide through DJ-1-related pathway in in vitro and in vivo models of Parkinson\u2019s disease. Mar. Drugs 14, E187 (2016).","journal-title":"Mar. Drugs"},{"key":"155_CR208","doi-asserted-by":"crossref","first-page":"E1107","DOI":"10.3390\/molecules21091107","volume":"21","author":"N Ablat","year":"2016","unstructured":"Ablat, N. et al. Neuroprotective effects of a standardized flavonoid extract from safflower against a rotenone-induced rat model of Parkinson\u2019s disease. Molecules 21, E1107 (2016).","journal-title":"Molecules"},{"key":"155_CR209","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms4828","volume":"5","author":"E Zavodszky","year":"2014","unstructured":"Zavodszky, E. et al. Mutation in VPS35 associated with Parkinson\u2019s disease impairs WASH complex association and inhibits autophagy. Nat. Commun. 5, 3828 (2014).","journal-title":"Nat. Commun."},{"key":"155_CR210","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuron.2017.03.020","volume":"94","author":"P Temkin","year":"2017","unstructured":"Temkin, P. et al. The retromer supports AMPA receptor trafficking during LTP. Neuron 94, 74\u201382 (2017).","journal-title":"Neuron"},{"key":"155_CR211","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1073\/pnas.1700465115","volume":"115","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. GBA1 deficiency negatively affects physiological \u03b1-synuclein tetramers and related multimers. Proc. Natl Acad. Sci. USA 115, 798\u2013803 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"155_CR212","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","volume":"59","author":"CW Shults","year":"2002","unstructured":"Shults, C. W. et al. Effects of coenzyme Q 10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59, 1541\u20131550 (2002).","journal-title":"Arch. Neurol."},{"key":"155_CR213","first-page":"543","volume":"75","author":"MF Beal","year":"2014","unstructured":"Beal, M. F. et al. A randomized clinical trial of high-dosage coenzyme Q10 in early parkinson disease no evidence of benefit. JAMA Neurol. 75, 543\u2013552 (2014).","journal-title":"JAMA Neurol."},{"key":"155_CR214","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroscience.2004.06.016","volume":"128","author":"MO Poulter","year":"2004","unstructured":"Poulter, M. O., Payne, K. B. & Steiner, J. P. Neuroimmunophilins: a novel drug therapy for the reversal of neurodegenerative disease? Neuroscience 128, 1\u20136 (2004).","journal-title":"Neuroscience"},{"key":"155_CR215","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1212\/01.wnl.0000250355.28474.8e","volume":"68","author":"K Kieburtz","year":"2007","unstructured":"Kieburtz, K. et al. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 68, 20\u201328 (2007).","journal-title":"Neurology"},{"key":"155_CR216","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3233\/JPD-161040","volume":"7","author":"LK Mischley","year":"2017","unstructured":"Mischley, L. K., Lau, R. C., Shankland, E. G., Wilbur, T. K. & Padowski, J. M. Phase IIb study of intranasal glutathione in Parkinson\u2019s disease. J. Parkinsons Dis. 7, 289\u2013299 (2017).","journal-title":"J. Parkinsons Dis."},{"key":"155_CR217","volume":"11","author":"DA Monti","year":"2016","unstructured":"Monti, D. A. et al. N-Acetyl cysteine may support dopamine neurons in Parkinson\u2019s disease: preliminary clinical and cell line data. PLOS ONE 11, e0157602 (2016).","journal-title":"PLOS ONE"},{"key":"155_CR218","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ana.24751","volume":"80","author":"KDer Lin","year":"2016","unstructured":"Lin, K. Der et al. Statin therapy prevents the onset of Parkinson disease in patients with diabetes. Ann. Neurol. 80, 532\u2013540 (2016).","journal-title":"Ann. Neurol."},{"key":"155_CR219","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/mds.27006","volume":"32","author":"G Liu","year":"2017","unstructured":"Liu, G. et al. Statins may facilitate Parkinson\u2019s disease: insight gained from a large, national claims database. Mov. Disord. 32, 913\u2013917 (2017).","journal-title":"Mov. Disord."},{"key":"155_CR220","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1212\/01.wnl.0000201252.57661.e1","volume":"66","author":"B Ravina","year":"2006","unstructured":"Ravina, B. et al. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66, 664\u2013671 (2006).","journal-title":"Neurology"},{"key":"155_CR221","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.bbadis.2013.09.007","volume":"1842","author":"H Jin","year":"2014","unstructured":"Jin, H. et al. Mitochondria-targeted antioxidants for treatment of Parkinson\u2019s disease: preclinical and clinical outcomes. Biochim. Biophys. Acta 1842, 1282\u20131294 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"155_CR222","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/mds.23148","volume":"25","author":"BJ Snow","year":"2010","unstructured":"Snow, B. J. et al. A double-blind, placebo-controlled study to assess the mitochondria- targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson\u2019s disease. Mov. Disord. 25, 1670\u20131674 (2010).","journal-title":"Mov. Disord."},{"key":"155_CR223","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-07181-0","volume":"7","author":"S Bido","year":"2017","unstructured":"Bido, S., Soria, F. N., Fan, R. Z., Bezard, E. & Tieu, K. Mitochondrial division inhibitor-1 is neuroprotective in the A53T-\u03b1-synuclein rat model of Parkinson\u2019s disease. Sci. Rep. 7, 7495 (2017).","journal-title":"Sci. Rep."},{"key":"155_CR224","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00401-018-1873-4","volume":"136","author":"A Shaltouki","year":"2018","unstructured":"Shaltouki, A., Hsieh, C. H., Kim, M. J. & Wang, X. Alpha-synuclein delays mitophagy and targeting Miro rescues neuron loss in Parkinson\u2019s models. Acta Neuropathol. 136, 607\u2013620 (2018).","journal-title":"Acta Neuropathol."},{"key":"155_CR225","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.parkreldis.2014.05.007","volume":"20","author":"T Paolo Di","year":"2014","unstructured":"Di Paolo, T. et al. AQW051, a novel and selective nicotinic acetylcholine receptor \u03b17 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Parkinsonism Relat. Disord. 20, 1119\u20131123 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"155_CR226","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/mds.26659","volume":"31","author":"F Tison","year":"2016","unstructured":"Tison, F. et al. A phase 2A trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson\u2019s disease. Mov. Disord. 31, 1373\u20131380 (2016).","journal-title":"Mov. Disord."},{"key":"155_CR227","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/mt.2010.135","volume":"18","author":"SI Muramatsu","year":"2010","unstructured":"Muramatsu, S. I. et al. A phase i study of aromatic l-amino acid decarboxylase gene therapy for parkinson\u2019s disease. Mol. Ther. 18, 1731\u20131735 (2010).","journal-title":"Mol. Ther."},{"key":"155_CR228","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1089\/hum.2011.220","volume":"23","author":"G Mittermeyer","year":"2012","unstructured":"Mittermeyer, G. et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson\u2019s disease. Hum. Gene Ther. 23, 377\u2013381 (2012).","journal-title":"Hum. Gene Ther."},{"key":"155_CR229","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","volume":"383","author":"D M.","year":"2014","unstructured":"Palfi, S. et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson\u2019s disease: a dose escalation, open-label, phase 1\/2 trial. Lancet 383, 1138\u20131146 (2014).","journal-title":"Lancet"},{"key":"155_CR230","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","volume":"369","author":"MG Kaplitt","year":"2007","unstructured":"Kaplitt, M. G. et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson\u2019s disease: an open label, phase I trial. Lancet 369, 2097\u20132105 (2007).","journal-title":"Lancet"},{"key":"155_CR231","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","volume":"9","author":"SS Gill","year":"2003","unstructured":"Gill, S. S. et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9, 589\u2013595 (2003).","journal-title":"Nat. Med."},{"key":"155_CR232","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3171\/jns.2005.102.2.0216","volume":"102","author":"JT Slevin","year":"2005","unstructured":"Slevin, J. T. et al. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line\u2014derived neurotrophic factor. J. Neurosurg. 102, 216\u2013222 (2005).","journal-title":"J. Neurosurg."},{"key":"155_CR233","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.20737","volume":"59","author":"AE Lang","year":"2006","unstructured":"Lang, A. E. et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59, 459\u2013466 (2006).","journal-title":"Ann. Neurol."},{"key":"155_CR234","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.20374","volume":"57","author":"NK Patel","year":"2005","unstructured":"Patel, N. K. et al. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: A two-year outcome study. Ann. Neurol. 57, 298\u2013302 (2005).","journal-title":"Ann. Neurol."},{"issue":"Suppl. 2","key":"155_CR235","first-page":"1420","volume":"32","author":"T. G. Study Group","year":"2017","unstructured":"T. G. Study Group. Randomized Parkinson\u2019s trial of GDNF administered via intermittent intraputamenal convection-enhanced delivery [abstract]. Mov. Disord. 32 (Suppl. 2), 1420 (2017).","journal-title":"Mov. Disord."},{"key":"155_CR236","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1212\/WNL.0b013e3182904faa","volume":"80","author":"RT Bartus","year":"2013","unstructured":"Bartus, R. T. et al. Safety\/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 80, 1698\u20131701 (2013).","journal-title":"Neurology"},{"key":"155_CR237","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ana.24436","volume":"78","author":"C Warren Olanow","year":"2015","unstructured":"Warren Olanow, C. et al. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann. Neurol. 78, 248\u2013257 (2015).","journal-title":"Ann. Neurol."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41582-019-0155-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41582-019-0155-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41582-019-0155-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T15:39:02Z","timestamp":1721057942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-019-0155-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,12]]},"references-count":237,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["155"],"URL":"https:\/\/doi.org\/10.1038\/s41582-019-0155-7","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735328024.793576746","asserted-by":"object"}]},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,12]]},"assertion":[{"value":"12 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.V.-M. is supported by a grant for the deep brain stimulation brain bank from Abbott. M.S.O. serves as a consultant for the Parkinson's Foundation and has received research grants from NIH, NPF, the Michael J. Fox Foundation, the Parkinson Alliance, the Smallwood Foundation, the Bachmann\u2013Strauss Foundation, the Tourette Syndrome Association and the UF Foundation. M.S.O. has previously received honoraria but in the past\u2009>60 months has received no support from industry. M.S.O. has received royalties for publications with Demos, Manson, Amazon, Smashwords, Books4Patients and Cambridge (movement disorder books). M.S.O. is an associate editor for the <i>New England Journal of Medicine: Journal Watch Neurology<\/i>. M.S.O. has participated in continuing medical education and educational activities on movement disorders (in the past 36 months) sponsored by PeerView, Prime, QuantiaMD, WebMD, Medicus, MedNet, Henry Stewart and Vanderbilt University. M.S.O. has participated as a site principal investigator (PI) and\/or co-PI for several NIH, foundation and industry-sponsored trials over the years but has not received honoraria. A.E. and R.S.E. have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}